Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

58364 1487845784HCLSReviewSingaporeFeb2017.pdf
Energy Boardroom

High court dashes Actelion's hopes for $407M reprieve in Tracleer case

13.03.2014 / Fierce Pharma

Actelion has lost its fight against a $407 million court judgment. California's Supreme Court rebuffed the Swiss drugmaker's appeal in a lawsuit over competition for its top-selling drug, the pulmonary arterial hypertension (PAH) treatment Tracleer. That affirms a lower court's ruling that Actelion intentionally thwarted a rival by acquiring a drug company and then spiking its prospective Tracleer competitor.

Cover_HCLS_Singapore LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: